[Development of human monoclonal antibodies. Current status and future development].
The "state of the art" in the development of human monoclonal antibodies is reported. The classical cellular fusion method according to well established procedures, the Epstein-Barr virus mediated B-lymphocyte transformation and the modern genetic engineering method to obtain chimeric antibodies is reviewed in detail. Although they were praised in the last five years as the most efficient drugs against cancer and infectious diseases, no great success was clinically and experimentally reported in the past. The many experimental obstacles hindered the efficient development of these promising drugs. In the last two years, however, new ways were proposed to get this new therapeutic principle on a more efficient way in order to use them in the therapeutic treatment of patients with certain cancer and infectious diseases.
Gebauer
W
W
Institut für angewandte Zellkultur, München.
Lindl
T
T
D000486:Allergy and Immunology / Q000639:trends*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D006801:Humans
D000911:Antibodies, Monoclonal
Entwicklung humaner monoklonaler Antikörper. Gegenwärtiger Stand und Entwicklungsaussichten.